ima203

Cancer

Immatics US, Inc.Phase 1/2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 65/ 100

Competitive context

1411 Active assets in the Cancer cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

ima203 is also rated in:

cutaneous melanomaDormant

B

Indicative ·

62 / 100

refractory malignant neoplasmDormant

CCC

Indicative ·

51 / 100

Solid Tumor, AdultDormant

CCC

Indicative ·

49 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.